News & Updates
Filter by Specialty:
Prasugrel tops ticagrelor for reducing risk of ischaemic events in ACS patients with prior MI
Prasugrel appears to better protect against the risk of ischaemic events in patients with acute coronary syndrome (ACS) and prior myocardial infarction (MI) as compared with ticagrelor, without a trade-off in bleeding, a study has found.
Prasugrel tops ticagrelor for reducing risk of ischaemic events in ACS patients with prior MI
24 Dec 2022
Pemafibrate reduces triglycerides, but not CV events, in patients with T2D, hypertriglyceridemia
Despite reducing triglyceride levels, pemafibrate does not reduce the risk of cardiovascular (CV) events among patients with type 2 diabetes (T2D) and hypertriglyceridemia, according to results of the PROMINENT trial presented at AHA 2022.
Pemafibrate reduces triglycerides, but not CV events, in patients with T2D, hypertriglyceridemia
23 Dec 2022
No excess pancreatic cancer risk with dihydropyridine calcium channel blockers, study says
Exposure to dihydropyridine calcium channel blockers does not appear to put patients at increased risk of developing pancreatic cancer as compared with thiazide diuretics, as shown in a large study.
No excess pancreatic cancer risk with dihydropyridine calcium channel blockers, study says
22 Dec 2022
Local data support continuation of RASIs in patients with T2D and advanced CKD
Discontinuation of renin-angiotensin system inhibitors (RASIs) is associated with higher risks of cardiorenal complications and neutral risk of all-cause mortality in patients with type 2 diabetes (T2D) and advanced chronic kidney disease (CKD), according to researchers from the Chinese University of Hong Kong (CUHK).
Local data support continuation of RASIs in patients with T2D and advanced CKD
22 Dec 2022
HF meds rapid up-titration reduces readmission, mortality after acute HF hospitalization
Rapidly maximizing medications in patients discharged from hospital following acute heart failure (AHF) reduced the risk of hospital readmission or death at 180 days, according to results of the STRONG-HF* trial presented at AHA 2022.
